• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Oncological Outcomes of Pathological T1 Lower Rectal Cancer Patients With or Without Preoperative Chemoradiotherapy.术前放化疗对 T1 期低位直肠癌患者的肿瘤学结局的影响。
In Vivo. 2020 Nov-Dec;34(6):3559-3564. doi: 10.21873/invivo.12199.
2
Prognoses in Pathologically Confirmed T1 Lower Rectal Cancer Patients with or without Preoperative Therapy: An Analysis Using the Surveillance, Epidemiology, and End Results Database.术前治疗与否的经病理证实的 T1 低位直肠癌患者的预后:基于监测、流行病学和最终结果数据库的分析。
Oncology. 2022;100(2):82-88. doi: 10.1159/000521033. Epub 2021 Nov 24.
3
Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.基于治疗前影像学检查,对接受术前放化疗的晚期低位直肠癌患者行选择性侧方盆腔淋巴结清扫术。
Ann Surg Oncol. 2014 Jan;21(1):189-96. doi: 10.1245/s10434-013-3216-y. Epub 2013 Aug 21.
4
Oncologic Outcome of ypT1-2N0 Rectal Cancer After Neoadjuvant Chemoradiotherapy Compared With pT1-2N0 Rectal Cancer.新辅助放化疗后ypT1-2N0直肠癌与pT1-2N0直肠癌的肿瘤学结局比较
Am J Clin Oncol. 2017 Oct;40(5):512-516. doi: 10.1097/COC.0000000000000196.
5
Endoscopic assessment of tumor regression after preoperative chemoradiotherapy as a prognostic marker in locally advanced rectal cancer.术前放化疗后肿瘤消退的内镜评估作为局部晚期直肠癌的预后标志物
Surg Oncol. 2017 Dec;26(4):453-459. doi: 10.1016/j.suronc.2017.09.002. Epub 2017 Sep 13.
6
Oncological Outcomes of Transanal Endoscopic Microsurgery Plus Adjuvant Chemoradiotherapy for Patients with High-Risk T1 and T2 Rectal Cancer.经肛门内镜微创手术联合辅助放化疗治疗高危 T1 和 T2 期直肠癌的肿瘤学结局。
J Laparoendosc Adv Surg Tech A. 2021 Sep;31(9):1006-1013. doi: 10.1089/lap.2020.0706. Epub 2020 Oct 7.
7
[Effects of neoadjuvant chemoradiotherapy on the rates of sphincter preserving surgery in lower rectal cancer and analysis of their prognostic factors].[新辅助放化疗对低位直肠癌保肛手术率的影响及其预后因素分析]
Zhonghua Wai Ke Za Zhi. 2016 Jun 1;54(6):419-423. doi: 10.3760/cma.j.issn.0529-5815.2016.06.005.
8
Pathologic Staging Inconsistency Between ypT4N0 (stage II) and ypT1-2N1 (stage III) After Preoperative Chemoradiotherapy and Total Mesorectal Excision in Rectal Cancer: A Multi-Institutional Study.直肠癌术前放化疗及全直肠系膜切除术后 ypT4N0(Ⅱ期)与 ypT1-2N1(Ⅲ期)病理分期不一致:多中心研究。
Clin Colorectal Cancer. 2019 Mar;18(1):e130-e139. doi: 10.1016/j.clcc.2018.11.003. Epub 2018 Nov 23.
9
Oncologic outcomes of pathologic stage I lower rectal cancer with or without preoperative chemoradiotherapy: are they comparable?术前放化疗与单纯手术治疗病理 I 期低位直肠癌的肿瘤学结局:两者可比吗?
Surgery. 2011 Nov;150(5):980-4. doi: 10.1016/j.surg.2011.06.018. Epub 2011 Aug 27.
10
Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12.癌胚抗原对直肠癌术前放化疗及根治性手术后的肿瘤降期和复发具有预后价值:KROG 14-12多机构病例匹配对照研究
Radiother Oncol. 2015 Aug;116(2):202-8. doi: 10.1016/j.radonc.2015.07.049. Epub 2015 Aug 21.

引用本文的文献

1
Study on Ultrasonographic Diagnosis and Postoperative Comprehensive Nursing of Rectal Cancer in Preoperative Staging.术前分期直肠癌的超声诊断及术后综合护理研究。
Contrast Media Mol Imaging. 2022 Jun 23;2022:7671169. doi: 10.1155/2022/7671169. eCollection 2022.
2
Prognoses in Pathologically Confirmed T1 Lower Rectal Cancer Patients with or without Preoperative Therapy: An Analysis Using the Surveillance, Epidemiology, and End Results Database.术前治疗与否的经病理证实的 T1 低位直肠癌患者的预后:基于监测、流行病学和最终结果数据库的分析。
Oncology. 2022;100(2):82-88. doi: 10.1159/000521033. Epub 2021 Nov 24.
3
Impact of Fluoropyrimidine and Oxaliplatin-based Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.氟尿嘧啶和奥沙利铂为基础的放化疗对局部晚期直肠癌患者的影响。
In Vivo. 2021 Jan-Feb;35(1):593-601. doi: 10.21873/invivo.12296.

本文引用的文献

1
Recent advances in neoadjuvant chemoradiotherapy in locally advanced rectal cancer.局部晚期直肠癌新辅助放化疗的最新进展
J Anus Rectum Colon. 2018 May 25;1(2):39-44. doi: 10.23922/jarc.2017-005. eCollection 2017.
2
Distinct Prognosis of High Versus Mid/Low Rectal Cancer: a Propensity Score-Matched Cohort Study.高位与中/低位直肠癌的不同预后:倾向评分匹配队列研究。
J Gastrointest Surg. 2019 Jul;23(7):1474-1484. doi: 10.1007/s11605-018-04072-1. Epub 2019 Jan 7.
3
Is adjuvant chemotherapy necessary for patients with ypT0-2N0 rectal cancer treated with neoadjuvant chemoradiotherapy and curative surgery?对于接受新辅助放化疗和根治性手术治疗的ypT0-2N0期直肠癌患者,辅助化疗是否必要?
Gastroenterol Rep (Oxf). 2018 Nov;6(4):277-283. doi: 10.1093/gastro/goy029. Epub 2018 Aug 13.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
Down-staging depth score to predict outcomes in locally advanced rectal cancer achieving ypI stage after neoadjuvant chemo-radiotherapy versus stage pI cohort: A propensity score-matched analysis.新辅助放化疗后达到ypI期的局部晚期直肠癌与pI期队列相比,用于预测结局的降期深度评分:一项倾向评分匹配分析。
Chin J Cancer Res. 2018 Jun;30(3):373-381. doi: 10.21147/j.issn.1000-9604.2018.03.09.
6
AJCC 8th Edition: Colorectal Cancer.美国癌症联合委员会第8版:结直肠癌
Ann Surg Oncol. 2018 Jun;25(6):1454-1455. doi: 10.1245/s10434-018-6462-1. Epub 2018 Apr 3.
7
YpT1-2N0 rectal cancer after neoadjuvant chemoradiation has lower survival compared with pT1-2N0 rectal cancer.新辅助放化疗后的ypT1-2N0期直肠癌与pT1-2N0期直肠癌相比,生存率较低。
Oncotarget. 2015 Dec 1;6(38):41056-62. doi: 10.18632/oncotarget.5379.
8
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.奥沙利铂联合氟尿嘧啶为基础的术前放化疗和局部进展期直肠癌术后化疗(德国 CAO/ARO/AIO-04 研究):多中心、开放标签、随机、III 期临床试验的最终结果。
Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.
9
Oncologic Outcome of ypT1-2N0 Rectal Cancer After Neoadjuvant Chemoradiotherapy Compared With pT1-2N0 Rectal Cancer.新辅助放化疗后ypT1-2N0直肠癌与pT1-2N0直肠癌的肿瘤学结局比较
Am J Clin Oncol. 2017 Oct;40(5):512-516. doi: 10.1097/COC.0000000000000196.
10
Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data.术前(放化疗)联合手术治疗直肠癌患者的辅助化疗:一项个体化患者数据的系统评价和荟萃分析。
Lancet Oncol. 2015 Feb;16(2):200-7. doi: 10.1016/S1470-2045(14)71199-4. Epub 2015 Jan 12.

术前放化疗对 T1 期低位直肠癌患者的肿瘤学结局的影响。

Oncological Outcomes of Pathological T1 Lower Rectal Cancer Patients With or Without Preoperative Chemoradiotherapy.

机构信息

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

出版信息

In Vivo. 2020 Nov-Dec;34(6):3559-3564. doi: 10.21873/invivo.12199.

DOI:10.21873/invivo.12199
PMID:33144468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7811633/
Abstract

BACKGROUND/AIM: It remains unclear whether rectal cancers down-staged by preoperative chemoradiotherapy (CRT) have similar prognoses to those of the same stage without preoperative CRT. We compared prognoses of pT1 rectal cancer patients stratified by preoperative CRT.

PATIENTS AND METHODS

We retrieved data of patients with pathological T1 rectal cancer between 2003 and 2020. Patients were divided into the "ypT1 group" who received preoperative CRT following surgery and the "pT1 group" who underwent surgery alone. Factors associated with relapse-free survival (RFS) were investigated.

RESULTS

Among 86 patients, ypT1 and pT1 groups comprised 18 and 68 patients, respectively. There was no significant difference in RFS between the groups (p=0.19). Tumor location within 5 cm from the anal verge was associated with recurrence (hazard ratio: 0.13, p=0.034).

CONCLUSION

The prognosis of patients with ypT1 rectal cancer was similar to that of patients with pT1. Low tumor location was a poor prognostic factor.

摘要

背景/目的:术前放化疗(CRT)降期的直肠癌与未经术前 CRT 的同分期直肠癌的预后是否相似仍不清楚。我们比较了经术前 CRT 分层的 pT1 直肠癌患者的预后。

患者和方法

我们检索了 2003 年至 2020 年间病理 T1 直肠癌患者的数据。患者被分为“ypT1 组”,即术后接受术前 CRT,以及“pT1 组”,即仅接受手术。研究了与无复发生存(RFS)相关的因素。

结果

在 86 名患者中,ypT1 组和 pT1 组分别有 18 名和 68 名患者。两组的 RFS 无显著差异(p=0.19)。距离肛门缘 5cm 以内的肿瘤位置与复发相关(风险比:0.13,p=0.034)。

结论

ypT1 直肠癌患者的预后与 pT1 患者相似。低位肿瘤是预后不良的因素。